RadioMedix Inc. Announces the Acquisition of Its 225Ac-PSMA I&T Program, a Targeted Alpha Therapy (TAT) for Metastatic Castration Resistant Prostate Cancer, by Fusion Pharmaceuticals Inc.

RadioMedix, Inc. announced the acquisition of its 225Ac-PSMA-I&T asset by Fusion Pharmaceuticals. RadioMedix will provide manufacturing support to Fusion for the TATCIST trial and the first pivotal clinical trial to evaluate the safety and efficacy of 225Ac-PSMA-I&T for metastatic castration-resistant prostate cancer.